GSK Reports Cobolimab Phase 3 Failure and Discontinues Multiple Drug Programs

August 2, 2025

Tessa Therapeutics dissolves company

July 10, 2023

Superbugs Could Be the Next Pandemic: We Need a Global, Comprehensive Plan to Address Them Now!

October 22, 2021

Must Read

What an Autonomous Clinical Trial Might Look Like by 2030

August 8, 2026

Takeda’s Orzeyful Approved as First Orexin Agonist for Narcolepsy Type 1

August 8, 2026

The biggest pharmaceutical deal ever would be the “unlikely” AstraZeneca-BMS mega-merger

August 6, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Merck’s Tulisokibart Misses Phase 2 Endpoint in SSc-ILD but Meets Goals in HS Trial

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

The biggest pharmaceutical deal ever would be the “unlikely” AstraZeneca-BMS mega-merger

Supernus and Indivior Agree to Create CNS-Focused Company in All-Stock Merger

Hinge Health to Buy Out Cylinder Health in a Deal Worth Over $100M

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

What an Autonomous Clinical Trial Might Look Like by 2030

From Data-Rich to Insight-Rich: Pharma’s Next Transformation

The New Competitive Advantage in Biopharma Isn’t Science Alone

Why Protocol Complexity Continues to Threaten Trial Success

Tag: GSK

With future in sight, GSK sells it stake in respiratory drug firm Innoviva

Editor Picks

GSK Reports Cobolimab Phase 3 Failure and Discontinues Multiple Drug Programs

Tessa Therapeutics dissolves company

Superbugs Could Be the Next Pandemic: We Need a Global, Comprehensive Plan to Address Them Now!

Must Read

What an Autonomous Clinical Trial Might Look Like by 2030

Takeda’s Orzeyful Approved as First Orexin Agonist for Narcolepsy Type 1

The biggest pharmaceutical deal ever would be the “unlikely” AstraZeneca-BMS mega-merger

Hot Topics

About Us

Follow Us